Urology Testing Expansion MDL has recently launched a line of testing for the field of Urology, signaling a growth focus in urological pathogen detection and associated resistance profiling. This presents a sales opportunity to cross-sell complementary urology-centric panels, integration with existing clinical workflows, and bundled services to urology practices and hospital systems.

ObGyn Diagnostic Access MDL emphasizes molecular testing for Obstetrics and Gynecology, including multi-pathogen detection from a single swab. Target opportunities exist with OB/GYN groups and maternal-fetal medicine clinics seeking comprehensive, non-invasive PCR panels and rapid turnaround for prenatal and gynecological infections.

Infectious Disease Focus As a CLIA-certified infectious disease reference lab with expertise in PCR-based diagnostics, MDL is positioned to collaborate on infectious disease testing programs, surveillance partnerships, and contract research for hospitals seeking high-sensitivity, high-specificity molecular assays for viral, fungal, and bacterial infections.

Strategic Partnerships MDL has existing affiliations with Genesis Biotechnology Group and has engaged in public–private collaborations (e.g., COVID-19 testing initiatives). Business development opportunities include joint venture laboratory services, contract testing for health systems, and aligned marketing to expand reference lab services through partner networks.

Scale and Reach With a midsize employee base and annual revenue in the seven-figure to low eight-figure range, MDL is ideal for phased expansion of test menus, automation-enabled workflows, and regional hospital contracts. Target health systems and multisite networks seeking scalable molecular diagnostics with multiple specimen types from single swabs.